Free Papers

Xen Gel Stent vs Preserflo MicroShunt in open-angle glaucoma (OAG)

Free Paper Details

First Author: M.Mackert GERMANY

Co Author(s):    S. Freissinger   M. Nobl   E. Vounotrypidis   S. Priglinger           

Abstract Details

Purpose:

Comparison of two novel glaucoma drainage devices with subconjunctival filtration (Xen and Microshunt) for OAG regarding effectiveness and safety.

Setting:

This single-centre, retrospective, comparative cohort study was performed at the Ludwig-Maximilians-University eye hospital, Munich, Germany.

Methods:

Primary endpoint was the intraocular pressure (IOP) reduction 3-4 months after surgery. Secondary endpoints were the reduction of glaucoma medications, intraoperative and postoperative adverse events and needling rate. For statistical analysis the Wilcoxon test (p less-than 0.05) and the multivariate analysis of variance (MANOVA) was performed using SPSS.

Results:

Seventy-eight eyes of 78 patients received either Xen (n=52) or Microshunt (n=26) to control IOP in OAG. IOP reduction after 3-4 months postoperative was statistically significant (p less-than 0.001) in both groups (mean -5,9mmHg versus -9mmHg) with a higher IOP lowering effect in the Microshunt group (p=0.031). A statistically significant reduction in glaucoma medications was achieved in both groups (p less-than 0.001) with an advantage in the Microshunt group (p=0.012). No severe adverse events were observed in any group. The needling rate was 23% in the Xen group and 17% in the Microshunt group.

Conclusions:

Xen and Microshunt are effective glaucoma draining devices significantly reducing both IOP and glaucoma medications in OAG. Overall, Microshunt seems to be a more effective treatment option in comparison with Xen in patients with OAG.

Financial Disclosure:

... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented